Clinical Trials And DevelopmentThe Phase 2 BREAKTHROUGH trial for BMB-101 in absence epilepsy and developmental and epileptic encephalopathies remains on track to deliver top-line data, potentially de-risking the program and paving the way for advancement to Phase 3.
Drug Design And EfficacyBMB-101's unique design as a G-protein–biased 5-HT agonist is engineered to sustain efficacy and reduce the risk of tolerance compared with legacy serotonergic drugs.
Market OpportunitiesAbsence seizures represent a blockbuster opportunity with about 75,000 patients in the US having forms of epilepsy where absence seizures predominate, and are poorly served by approved medications.